Paradox of possibilities: the rare landscape in the Asia Pacific Region

Abstract

The Asia-Pacific (APAC) region, home to 60% of the global population, has the highest number of Persons Living with a rare disease (PLWRD). To promote more equitable societies, the Asia Pacific rare disease Organization (APARDO), established in 2015, has been developing its regional position to promote collaboration, increase awareness among stakeholders, explore equitable and affordable diagnosis and treatment, and improve health outcomes and quality of life for all PLWRD. The APAC region’s heterogeneous population and complex healthcare environment pose distinctive challenges in addressing rare diseases. Through conferences, webinars, and contributions to global initiatives, APARDO is fostering connectivity and providing a platform as a part of the global rare disease (RD) community to address shared challenges. The development of APARDO to strengthen its global presence as the representative of the APAC RD region is vital for a more equitable world.

Keywords

RDs / patient organizations / Asia-Pacific / policy / diversity

References

[1] Asia population 2024. Available from: https://worldpopulationreview.com/continents/asia-population [Last accessed on 28 Feb 2024].

[2] News & insights. Rare disease care across Asia Pacific. 2023. Available from: https://sandpipercomms.com/health/rare-disease-care-across-asia-pacific/ [Last accessed on 28 Feb 2024].

[3] Jain R. Rare diseases in Asia and the Pacific must be tackled too. Asia Pathways. 2020. Available from: https://www.asiapathways-adbi.org/2020/07/rare-diseases-asia-pacific-must-be-tackled-too/ [Last accessed on 28 Feb 2024].

[4] The Economist Intelligence Unit. Suffering in silence: assessing rare disease awareness and management in Asia-Pacific. 2020. Available from: https://www.cslbehring.com.au/-/media/shared/economist-white-paper/eng_white-paper_a4_digital_final.pdf [Last accessed on 28 Feb 2024].

[5] Shafie AA,Hassali MAA.Correction: rare disease in Malaysia: challenges and solutions.PLoS One2022;17:e0273939 PMCID:PMC9416982

[6] Chung CCY.Chu ATWChung BHYRare disease emerging as a global public health priority.Front Public Health2022;10:1028545 PMCID:PMC9632971

[7] Shafie AA,Supian A,Zafra M.State of rare disease management in Southeast Asia.Orphanet J Rare Dis2016;11:107 PMCID:PMC4969672

[8] Wong-Rieger D,Vines R,Tsang KP.An Asia pacific alliance for rare diseases.Patient2015;8:11-7

[9] Dharssi S,Harold M.Review of 11 national policies for rare diseases in the context of key patient needs.Orphanet J Rare Dis2017;12:63 PMCID:PMC5374691

[10] Khosla N.A compilation of national plans, policies and government actions for rare diseases in 23 countries.Intractable Rare Dis Res2018;7:213-22 PMCID:PMC6290840

[11] Chan AYL,Olsson S.Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis.Value Health2020;23:1580-91

[12] Gammie T,Babar ZU.Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries.PLoS One2015;10:e0140002 PMCID:PMC4599885

[13] Manatū Hauora. Rare disorders strategy. Available from: https://www.health.govt.nz/our-work/diseases-and-conditions/rare-disorders-strategy [Last accessed on 28 Feb 2024].

[14] UNFPA. Population trends. Available from: https://asiapacific.unfpa.org/en/populationtrends#:~:text=The%20Asia%20and%20the%20Pacific,populous%20countries%2C%20China%20and%20India [Last accessed on 29 Feb 2024].

[15] Statista. Total population in the Asia-Pacific region in 2022, by country or territory. Available from: https://www.statista.com/statistics/632565/asia-pacific-total-population-by-country/ [Last accessed on 28 Feb 2024].

[16] Ministry of Health and Family Welfare. Steps taken for treatment of patients suffering from rare diseases. 2023. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1942712 [Last accessed on 28 Feb 2024].

[17] Digital portal for crowdfunding & voluntary donations for patients of rare diseases. Available from: https://rarediseases.mohfw.gov.in/Hospital_Treating_Rare_Diseases [Last accessed on 28 Feb 2024].

[18] Ministry of Chemicals and Fertilizers. Dr Mansukh Mandaviya launches national policy on research and development and innovation in pharma-MedTech sector in India and Scheme for promotion of research and innovation in pharma MedTech sector (PRIP). Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1960812 [Last accessed on 28 Feb 2024].

[19] First Chinese catalog of rare diseases. 2018. Available from: https://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5435167.htm [Last accessed on 28 Feb 2024].

[20] Second Chinese catalog of rare diseases. 2023. Available from: https://www.gov.cn/zhengce/zhengceku/202309/content_6905273.htm [Last accessed on 28 Feb 2024]

[21] CHARD. 2023. Available from: https://www.chard.org.cn/detail/news/1941 [Last accessed on 28 Feb 2024].

[22] Available from: https://www.gov.cn/zhengce/zhengceku/2019-10/08/content_5436962.htm [Last accessed on 28 Feb 2024].

[23] Guo J,Chen L.Administrative group of national rare diseases registry system of ChinaNational rare diseases registry system (NRDRS): China’s first nation-wide rare diseases demographic analyses.Orphanet J Rare Dis2021;16:515 PMCID:PMC8684272

[24] Yayasan MPS & Penyakit Langka. Official opening of indonesia center of excellence for rare diseases. 2017. Available from: https://www.penyakitlangkaindonesia.org/events/official-opening-indonesia-center-excellence-rare-diseases [Last accessed on 28 Feb 2024].

[25] Act on medical care for patients with intractable diseases. 1993. Available from: https://www.japaneselawtranslation.go.jp/ja/laws/view/3363 [Last accessed on 28 Feb 2024].

[26] Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices. 1960. Available from: https://www.japaneselawtranslation.go.jp/ja/laws/view/3213 [Last accessed on 28 Feb 2024].

[27] Republic act No. 10747. An act promulgating a comprehensive policy in addressing the needs of persons with rare disease. 2016. Available from: https://www.officialgazette.gov.ph/2016/03/03/republic-act-no-10747/ [Last accessed on 28 Feb 2024].

[28] Manalansan A. Rare diseases: patients should not be left behind. BusinessWorld. 2022. Available from: https://www.bworldonline.com/opinion/2022/02/01/427221/rare-diseases-patients-should-not-be-left-behind/ [Last accessed on 28 Feb 2024].

[29] Republic act no. 9288. An act promulgating a comprehensive policy and a national system for ensuring newborn screening. 2004. Available from: https://lawphil.net/statutes/repacts/ra2004/ra_9288_2004.html [Last accessed on 28 Feb 2024].

[30] Law No. 105/2016/QH13. 2016. Available from: https://vss.gov.vn/english/legal/pages/default.aspx?ItemID=3550 [Last accessed on 28 Feb 2024].

[31] Nature Portfolio. Fast-tracking rare disease diagnosis and treatment. Available from: https://www.nature.com/articles/d42473-020-00209-6 [Last accessed on 28 Feb 2024].

[32] Sciascia S,Salvatore M.Unmet needs in countries participating in the undiagnosed diseases network international: an international survey considering national health care and economic indicators.Front Public Health2023;11:1248260 PMCID:PMC10562568

[33] Kim MJ,Lee H.The Korean genetic diagnosis program for rare disease phase II: outcomes of a 6-year national project.Eur J Hum Genet2023;31:1147-53 PMCID:PMC10545669

[34] Pharmaceutical affairs act. Available from: https://elaw.klri.re.kr/eng_mobile/viewer.do?hseq=57508&type=sogan&key=10 [Last accessed on 28 Feb 2024].

[35] Ministry of Food and Drug Safety Notice. Regulation on designation of orphan drugs. 2018. Available from: https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71453 [Last accessed on 28 Feb 2024].

[36] Kang D.Horizontal healthcare utilization inequity in patients with rare diseases in Korea.Int J Equity Health2023;22:93 PMCID:PMC10190067

[37] Appendix 13: designation and registration of orphan medicines. Available from: https://www.npra.gov.my/easyarticles/images/users/1153/drgd_appendices/APPENDIX-13-Designation-and-Registration-of-Orphan-Medicines.pdf [Last accessed on 28 Feb 2024].

[38] Shafie AA,Ahmad Hassali MA.Rare disease in Malaysia: challenges and solutions.PLoS One2020;15:e0230850 PMCID:PMC7117672

[39] Parajuli N,Jain R.Genodermatoses picture: difficulties faced and way forward in Nepal.J Nepal Health Res Counc2023;20:1008-12

[40] Pandey AS. Case reports of metabolic disorders from Nepal.Mol Genet Metab Rep2019;21:100542 PMCID:PMC6880005

[41] Australian Government Department of Health and Aged Care. National strategic action plan for rare diseases. 2020. Available from: https://www.health.gov.au/resources/publications/national-strategic-action-plan-for-rare-diseases?language=en [Last accessed on 28 Feb 2024].

[42] Rare Voices Australia. Implementing the national strategic action plan for rare diseases. May 2023 status report. 2023. Available from: https://rarevoices.org.au/wp-content/uploads/2023/05/Implementing-the-National-Strategic-Action-Plan-for-Rare-Diseases_May-2023-Status-Report.pdf [Last accessed on 28 Feb 2024].

[43] Department of Health and Aged Care. Pharmaceutical benefits scheme (PBS).

[44] Australian Government Department of Health and Aged Care. About the life saving drugs program. 2023. Available from: https://www.health.gov.au/our-work/life-saving-drugs-program/about-the-lsdp [Last accessed on 28 Feb 2024].

[45] Government response. The new frontier: inquiry into approval processes for new drugs and novel medical technologies in Australia. 2023. Available from: https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Newdrugs/Government_Response [Last accessed on 28 Feb 2024].

[46] Ministry of Health and Welfare. The Rare disease and orphan drug act. 2015. Available from: https://law.moj.gov.tw/ENG/LawClass/LawAll.aspx?pcode=L0030003 [Last accessed on 28 Feb 2024].

[47] Hsiang NC,Gau CS,Chang LC.The impact of the rare disease and orphan drug act in Taiwan.J Food Drug Anal2021;29:717-25. PMCID:PMC9931014

[48] Adachi T,Jain R.Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges.Int J Environ Res Public Health2023;20:4732 PMCID:PMC10049067

[49] LCQ20: policies and measures on rare diseases. Available from: https://www.info.gov.hk/gia/general/202105/05/P2021050500461.htm [Last accessed on 28 Feb 2024].

[50] Chung CCY,Ng YNC.Socio-economic costs of rare diseases and the risk of financial hardship: a cross-sectional study.Lancet Reg Health West Pac2023;34:100711 PMCID:PMC10240356

[51] Orphan Drugs & Rare Diseases. Drew & Napier/Singapore. Available from: https://pharmaboardroom.com/legal-articles/orphan-drugs-rare-diseases-singapore/ [Last accessed on 28 Feb 2024].

[52] Minister for Health. Singaporeans diagnosed with rare diseases and coverage by rare disease fund. 2023. Available from: https://www.moh.gov.sg/news-highlights/details/singaporeans-diagnosed-with-rare-diseases-and-coverage-by-rare-disease-fund [Last accessed on 28 Feb 2024].

[53] Rare Disease Fund. What is the rare disease fund? Available from: https://www.kkh.com.sg/giving/Documents/Rare-Disease-Fund/index.html [Last accessed on 28 Feb 2024].

[54] Agency for Care Effectiveness. Drug and vaccine evaluation methods and process guide. 2023. Available from: https://www.ace-hta.gov.sg/docs/default-source/process-methods/drug-and-vaccine-evaluation-methods-and-process-guide-version-3-1-(september-2023).pdf [Last accessed on 28 Feb 2024].

[55] Pae Ora (healthy futures) bill. Government bill 85-3. 2021. Available from: https://legislation.govt.nz/bill/government/2021/0085/latest/whole.html#LMS575405 [Last accessed on 28 Feb 2024].

[56] Priority lists for funding applications. Available from: https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/priority-lists [Last accessed on 28 Feb 2024].

[57] Funding for rare disorders. Available from: https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/from-application-to-funded-medicine-how-we-fund-a-medicine/medicines-for-rare-disorders [Last accessed on 28 Feb 2024].

[58] The Pharmac Review. Available from: https://pharmac.govt.nz/about/pharmacreview [Last accessed on 28 Feb 2024].

[59] New Zealand Health Strategy. 2023. Available from: https://www.health.govt.nz/publication/new-zealand-health-strategy [Last accessed on 28 Feb 2024].

[60] Provisional Health of Disabled People Strategy. 2023. Available from: https://www.health.govt.nz/publication/provisional-health-disabled-people-strategy [Last accessed on 28 Feb 2024].

[61] Rare Disorders New Zealand. Rare support centre aotearoa. 2023. Available from: https://www.raredisorders.org.nz/assets/Documents/RSCA-centre-of-expertise-131123-v2.pdf [Last accessed on 28 Feb 2024].

[62] Chung CCY,Jain R.A thematic study: impact of COVID-19 pandemic on rare disease organisations and patients across ten jurisdictions in the Asia Pacific region.Orphanet J Rare Dis2021;16:119 PMCID:PMC7935006

[63] Chung CC,Fung JL,Chung BH.Impact of COVID-19 pandemic on patients with rare disease in Hong Kong.Eur J Med Genet2020;63:104062 PMCID:PMC7486880

[64] Padilla CD,Alcausin MMLB.Successful implementation of expanded newborn screening in the Philippines using tandem mass spectrometry.Int J Neonatal Screen2022;8:8 PMCID:PMC8883932

[65] Political declaration of the high-level meeting on universal health coverage. Universal health coverage: moving together to build a healthier world. Available from: https://www.un.org/pga/73/wp-content/uploads/sites/53/2019/07/FINAL-draft-UHC-Political-Declaration.pdf [Last accessed on 28 Feb 2024].

[66] UN. General Assembly (76th sess.: 2021-2022). Addressing the challenges of persons living with a rare disease and their families: resolution/adopted by the general assembly. 2021. Available from: https://digitallibrary.un.org/record/3953765?ln+=+en&ln=ar [Last accessed on 28 Feb 2024].